Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

SG Archer; A Eliopoulos; D Spandidos; D Barnes; IO Ellis; RW Blamey; RI Nicholson; JFR Robertson

doi:10.1038/bjc.1995.497

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

British Journal of Cancer ◽

10.1038/bjc.1995.497 ◽

1995 ◽

Vol 72 (5) ◽

pp. 1259-1266 ◽

Cited By ~ 91

Author(s):

SG Archer ◽

A Eliopoulos ◽

D Spandidos ◽

D Barnes ◽

IO Ellis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormonal Therapy ◽

Advanced Breast ◽

First Line ◽

Ras P21

Download Full-text

Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

The Breast ◽

10.1016/0960-9776(93)90119-z ◽

1993 ◽

Vol 2 (3) ◽

pp. 198-199 ◽

Cited By ~ 3

Author(s):

R. Peréz-Carrion ◽

V. Alberola ◽

F. Calabresi ◽

R-Th. Michel ◽

R. Santos ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Randomized Trial ◽

Aromatase Inhibitor ◽

Hormonal Therapy ◽

Advanced Breast ◽

First Line

Download Full-text

68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival

The Breast ◽

10.1016/0960-9776(95)90160-4 ◽

1995 ◽

Vol 4 (3) ◽

pp. 246

Author(s):

C.M. Royce ◽

L. Mauriac ◽

R. Pérez Carrion ◽

V. Alberola ◽

F. Calabresi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Randomized Trial ◽

Aromatase Inhibitor ◽

Hormonal Therapy ◽

Advanced Breast ◽

First Line

Download Full-text

CN1 A STOCHASTIC ECONOMIC EVALUATION OF LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY

Value in Health ◽

10.1016/s1098-3015(10)61193-x ◽

2002 ◽

Vol 5 (6) ◽

pp. 443 ◽

Cited By ~ 2

Author(s):

FU Fricke ◽

K Quednau ◽

O Pirk

Keyword(s):

Breast Cancer ◽

Economic Evaluation ◽

Advanced Breast Cancer ◽

Hormonal Therapy ◽

Advanced Breast ◽

First Line

Download Full-text

Cost Utility Analysis of First-Line Hormonal Therapy in Advanced Breast Cancer

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000021042.55557.2b ◽

2003 ◽

Vol 26 (3) ◽

pp. 289-296 ◽

Cited By ~ 7

Author(s):

George Dranitsaris ◽

Shailendra Verma ◽

Maureen Trudeau

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormonal Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Advanced Breast ◽

Utility Analysis ◽

First Line

Download Full-text

365 Randomized trial between selective aromatase inhibitor formestane (®lentaron) vs tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: Confirmation of bioequivalence in survival

European Journal of Cancer ◽

10.1016/0959-8049(95)95618-g ◽

1995 ◽

Vol 31 ◽

pp. S80

Author(s):

L. Mauriac ◽

R. Pérez Carrion ◽

V. Alberola ◽

F. Calabresi ◽

R.Th. Michel ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Randomized Trial ◽

Aromatase Inhibitor ◽

Hormonal Therapy ◽

Advanced Breast ◽

First Line

Download Full-text

FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct03944434 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Older Patients ◽

Advanced Breast ◽

First Line

Download Full-text

Faculty Opinions recommendation of Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726825231.793525691 ◽

2016 ◽

Author(s):

Jennifer Litton

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer

10.21873/anticanres.12000 ◽

2017 ◽

Vol 37 (10) ◽

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover

European Journal of Cancer ◽

10.1016/0959-8049(95)95599-2 ◽

1995 ◽

Vol 31 ◽

pp. S75 ◽

Cited By ~ 1

Author(s):

R. Paridaens ◽

P. Bruning ◽

F. Calabresi ◽

A. Awada ◽

J.A. Roy ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

First Line ◽

Randomized Phase Ii ◽

Line Chemotherapy

Download Full-text

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)

European Journal of Cancer ◽

10.1016/j.ejca.2006.08.020 ◽

2006 ◽

Vol 42 (18) ◽

pp. 3178-3185 ◽

Cited By ~ 12

Author(s):

L. Beex ◽

C. Rose ◽

H. Mouridsen ◽

J. Jassem ◽

M. Nooij ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Medroxyprogesterone Acetate ◽

Advanced Breast ◽

Phase Iii ◽

Endocrine Treatment ◽

First Line ◽

Phase Iii Study

Download Full-text